Alzheimer's Association: FDA Advisory Committee Unanimously Confirms Efficacy and Clinical Benefit of Leqembi for Early Alzheimer's Disease
June 10, 2023
June 10, 2023
CHICAGO, Illinois, June 10 (TNSgov) -- The Alzheimer's Association issued the following news release on June 9, 2023:
Today, an Advisory Committee to the Food and Drug Administration (FDA) unanimously endorsed the efficacy and clinical benefit of lecanemab (Leqembi(TM), Eisai) as part of the traditional approval process for this treatment.
"The Alzheimer's Association welcomes and celebrates this action by the FDA Advisory Committee to support traditional . . .
Today, an Advisory Committee to the Food and Drug Administration (FDA) unanimously endorsed the efficacy and clinical benefit of lecanemab (Leqembi(TM), Eisai) as part of the traditional approval process for this treatment.
"The Alzheimer's Association welcomes and celebrates this action by the FDA Advisory Committee to support traditional . . .